Efficacy and Safety of Roxadustat in Patients with Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials including 6,518 Patients

Table 4

TEAEs occurring in the treatment groups in DD study.

Parameter	value for heterogeneity (, )	RR (95% CI)	value
TEAEs	,	1.04 (0.96, 1.13)
Serious TEAEs	,	1.09 (0.97, 1.23)
Drug-related serious TEAEs	,	1.10 (0.96, 1.26)
Upper respiratory tract infection	,	1.07 (0.70, 1.64)
Urinary tract infection	,	1.76 (0.71, 4.40)
Pneumonia	,	1.03 (0.77, 1.37)
Hypertension	,	1.13 (0.93, 1.37)
Hypertensive crisis	,	0.79 (0.39, 1.60)
Hyperkalemia	,	1.03 (0.80, 1.33)
Headache	,	1.22 (0.92, 1.62)
Chest discomfort	,	3.31 (0.21, 52.28)
Vomiting	,	1.77 (1.08, 2.90)
Nausea	,	1.48 (0.83, 2.65)
Asthenia	,	2.30 (0.67, 7.87)
Alanine aminotransferase increase	,	1.48 (0.55, 3.98)
Dizziness	,	1.02 (0.65, 1.60)
Hypotension	,	1.45 (1.08, 1.96)
Muscle spasms	,	0.63 (0.28, 1.39)
Anemia	,	1.07 (0.63, 1.83)
Atrial fibrillation	,	0.81 (0.48, 1.37)
Diarrhea	,	1.40 (1.07, 1.82)
Constipation	,	1.51 (0.91, 2.50)
Pruritus	,	1.36 (0.80, 2.30)
Peritonitis	,	0.82 (0.40, 1.66)
Hyperparathyroidism secondary	,	1.09 (0.73, 1.64)
Injury, poisoning, and procedural complications	,	0.87 (0.68, 1.11)
Arteriovenous fistula thrombosis	,	1.43 (1.09, 1.87)
Coronary artery disease	,	0.22 (0.04, 1.35)
Acute myocardial infarction	,	0.59 (0.29, 1.21)
Cardiac failure	,	0.39 (0.17, 0.89)
Gastroenteritis	,	1.06 (0.26, 4.29)
Pancreatitis	,	4.99 (0.73, 34.09)
Cellulitis	,	0.82 (0.25, 2.75)
Sepsis	,	1.12 (0.60, 2.09)
Gangrene	,	1.34 (0.54, 3.29)

TEAEs: treatment emerged adverse event.